press release

August 24, 2022

– Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies – – Served as Chief Scientific Officer and a Director of Bristol Myers Squibb – CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 24, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings ...

press release

July 28, 2022

− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® (33% Growth vs. Same Period Last Year) – − Received FDA Approval of AMVUTTRA™ (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin Mediated Amyloidosis in Adults – − Expects to Report Topline Results from APOLLO B Phase 3 Trial of Patisiran in Patients ...

press release

July 22, 2022

Positive Opinion Based on HELIOS A Phase 3 Study European Commission Decision Expected in September 2022 CAMBRIDGE, Mass. (BUSINESS WIRE) Jul. 22, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval ...

press release

May 23, 2022

– New Exploratory Findings from 18 Month Analysis of HELIOS A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – – Improvements in NT proBNP and Echocardiographic Parameters Seen in Cardiac Subpopulation – – Reductions in Technetium Uptake Observed in Patients with High Grade Uptake at Baseline – CAMBRIDGE, Mass. (BUSINESS WIRE) ...

news

May 9, 2022

We are living in a golden age of medicine innovation, both for rare and prevalent diseases that present public health challenges. New technologies being developed by companies in the biotechnology sector offer hope for previously “undruggable” diseases, with dozens of new therapies gaining approval each year, and a steady stream of medical advances which offer the future potential of others. ...

press release

April 28, 2022

− Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Reported Positive 18 Month Results from HELIOS A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – − Announced 3 Month Extension of Review Period for New Drug Application for Vutrisiran due to Amendment to Address Pending Inspection Classification ...

news

April 15, 2022

This past year marked a historic chapter in Alnylam’s journey, and I’m honored to be providing this summary as the new CEO of Alnylam, having taken the helm from founding CEO John Maraganore at the end of 2021. 2021 was a year in which we saw tremendous progress with our commercial and pipeline performance, along with important steps forward ...

press release

February 10, 2022

− Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Million, Respectively, Representing 83% Annual Growth Compared to 2020 – − Reported Positive 18 Month Results from HELIOS A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – – Provides 2022 Combined Net Product Revenue Guidance of $900 Million to $1 Billion, ...

news

February 4, 2022

We are pleased and honored to have been named a Gold Team Massachusetts Economic Impact Award winner for 2022 by MassEcon, for our continued investment in our Norton (MA) manufacturing facility. The MassEcon awards recognize companies that are committed to and invest in job creation in Massachusetts and the development of the state's 21st century workforce. As a Massachusetts ...

press release

January 21, 2022

– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo – – Vutrisiran Continued to Demonstrate Halting or Reversal of Polyneuropathy, with Improvements in Neuropathy Impairment and QoL Relative to Baseline – – Exploratory Cardiac Data, Including Reduced Technetium Uptake Relative ...